To main content To main navigation

PPP Funding Programs

 The program to empower and advance UMCG's public-private partnerships. Facility
The program to empower and advance UMCG's public-private partnerships.
The UMCG's Public-Private Partnerships (PPP) funding programs aim to encourage researchers and companies to collaborate in research and development projects.

The Dutch Ministry of Economic Affairs and Health~Holland make available funding to the UMCG for the PPP Allowance scheme and the PPP Innovation subsidy scheme on an annual basis. Within the UMCG, the programs are coordinated by the UMCG Innovation Center. The funding options can be applied to support and extend the goals of a joint project by adding experiments, personnel and/or consumables that can strengthen the success of the project and contribute to establish a long-term partnership with the private partner(s). Both schemes are tailored to diverse types of initiatives and partnerships.

  • The Top Sector Life Sciences & Health (LSH), also known as Health~Holland, stimulates innovative research by (financially) supporting public-private partnerships (PPPs) in the LSH sector. With this Program Call, parties are encouraged to jointly set up Programs in which PPP projects are selected and implemented with the aim of developing sustainable innovative products and services within the LSH sector that contribute to the economic growth of the Netherlands. Within a Program, the organising parties are given the opportunity to select PPP projects for the relevant PPP subsidy that contribute to the goals of the Top Sector Life Sciences & Health.  Information about the funding call: Funding Opportunities | Health~Holland

    Many Programs have been awarded and will provide new funding opportunities.  For the full list of programs awarded by Health~Holland, please see Programs | Health~Holland.

    Below, you will find more information on the PPS programs in which the UMCG is the main coordinator, or one of the program partners.

    • FORESIGHT: A Public-Private Partnership for Drug Development
    • DEMTECH: Innovative technologies for home living people with dementia
    • IMPACT: Innovative machine perfusion for advancing clinical transplantation
    • ORANGEHealth- Shape the future of oral and general health
       

  • The PPP Innovation Subsidy is made possible through funding from Health Holland, the communication portal for the Top Sector Life Sciences & Health (LSH), under the Dutch Ministry of Economic Affairs and Climate Policy. A total budget of €1.7 million has been allocated for this Pilot Call, providing substantial financial support to advance innovative research partnerships.

    Following a selection process, UMCG Innovation Center has identified 7 projects that will receive funding under this Call. These projects, set to start shortly, span a diverse range of research areas, all with strong potential for societal, scientific, and economic impact. The selected projects primarily focus on industrial research, reflecting a high level of innovation and translational potential. They bring together a diverse range of companies, including several regional industries, highlighting UMCG’s commitment to public-private partnerships within the Northern Netherlands.

    Diverse Research Areas and Regional Collaboration

    1. Balto - Samen Beter Worden
      This project evaluates Balto, a digital tool designed to support patients undergoing allogeneic stem cell transplantation. By improving treatment adherence through personalised guidance, it aims to enhance patient outcomes and ease the burden on healthcare providers.
      Partners: University Medical Center Groningen, Obseq BV
    2. Computational-Modelling to Enhance Ergometer Design for Patients with Limb Loss
      This project explores the potential of musculoskeletal-modelling to improve design processes of medical devices, specifically arm-leg ergometers for patients with lower limb loss. By using computer simulations instead of multiple physical prototypes, we aim to create a more efficient design process and validated ergometer for patients with lower limb loss.
      Partners: University Medical Center Groningen, Lode BV, Umaco BV
    3. ProBalance - Propulsion optimization through improved seated balance in wheelchairs
      This project, a collaboration between UMCG and Vicair, aims to optimize seated balance and propulsion biomechanics in wheelchair users while reducing pressure distribution and shear forces. This public-private partnership brings research and development in the field of wheelchair seating together, leverages innovations in seated balance and its quantification.
      Partners: University Medical Center Groningen, VICAIR
    4. PReeclamptic Endothelial Conditions: Investigating Specific Endothelial markers for Risk assessment (PRECISE-R)
      Preeclampsia, a severe pregnancy complication, lacks clear causes and effective treatments. We aim to validate ESM-1 and GBP-1 as diagnostic or predictive markers, study their roles in preeclampsia, and develop tools for early detection, improving maternal-fetal outcomes and reducing healthcare costs.
      Partners: University Medical Center Groningen, IQ Products BV
    5. TITAN - Two-in-one Infusion Technology for Alleviating Nurses
      UMCG and Ivy Medical join forces to advance the Ivy Duo+, an innovative infusion pump integrating high-precision and large-volume capabilities. Aiming to improve nursing efficiency and patient safety, this transformative technology addresses critical healthcare challenges and will be validated through a clinical pilot study.
      Partners: University Medical Center Groningen, IvyMedical
    6. GUARD-IT: Generating Unique Single Domain Antibody-based Chimeric Antigen Receptors for Directed ImmunoTherapy
      Chimeric Antigen Receptor (CAR)-T cells are patient T cells modified ex vivo to target and kill cancer cells. The UMCG has developed decentralized Point-of-Care CAR-T manufacturing as a rapid and cost-effective therapeutic option. Within GUARD-IT the UMCG and Cortalix develop novel single domain antibody (sdAb)-based CAR-T cell therapeutics.
      Partners: University Medical Center Groningen, Cortalix BV
    7. The Axiom System: magnetic navigation for safer and faster endovascular treatment
      The Axiom System is an innovative technology that enables precise and autonomous guidewire navigation using magnetic control. By reducing manual manipulation, radiation exposure, and contrast agent use, it improves patient safety and procedural outcomes in endovascular treatments.
      Partners: University Medical Center Groningen, Flux Robotics

  • The old PPP allowance program has been terminated, due to the fact that the funding allocated by Health-Holland to the UMCG has been awarded and completed towards numerous projects throughout the years. At the moment, considering the absence of available funding, we are no longer receiving project applications. Please note that the Innovation Center and the PPP allowance team are working on identifying and developing new funding opportunities, provided by Health Holland on supporting public-private partnerships. More information on the availability of funding will be communicated within the coming months.